Peptide Therapeutics Market size is estimated to reach $48.2 billion by 2026, growing at a CAGR of 9.4% during the forecast period 2021-2026. Peptides are short chains of amino acids that perform many roles within the cell, such as anti-infectives and signaling. These therapeutics have the ability to treat various conditions from peptide replacement to antivirals. Peptide therapeutics are increasingly being adopted across the world owing to the rise in the prevalence of gastrointestinal disorders, cancer, and metabolic disorders.
The rise in the prescription of peptide therapeutics for the treatment of cancer, increasing adoption of generic peptides for various infectious diseases owing to its cost-effectiveness, rise in the adoption of peptides as medical diagnostic devices, and growing investment by the key players to develop advanced peptide therapeutics are the factors that are set to drive the growth of the Peptide Therapeutics Market for the period 2021-2026.
Peptide Therapeutics Market Segment Analysis-By Type
The Peptide Therapeutics Market based on the Type can be further segmented into Generic and Branded. The Branded segment held the largest share in 2020 owing to the factors such as the rise in the number of infectious diseases and the increase in the demand for original products in developed nations. The growing investments by the key players in research and development activities for the development of novel drugs is driving the growth of the Peptide Therapeutics Market.
The Generic segment is estimated to be the fastest growing segment with a CAGR of 10.6% over the period 2021-2026. This growth is owing to the factors such as the growing expenditure on healthcare by the governments, increase in the demand for generic peptides, and the rise in the product launches by key players.
Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=17367
Report Price: $ 4500 (Single User License)
Peptide Therapeutics Market Segment Analysis-By Application
The Peptide Therapeutics Market based on the Application can be further segmented into Gastrointestinal Disorders, Cancer, Metabolic Disorders, Neurological Disorders, and Others. The Cancer segment held the largest share in 2020 owing to the factors such as increase in the prescription of peptide therapeutics for the treatment of cancer and rise in the investment by the key players to develop advanced peptide therapeutics for cancer treatment.
The rise in awareness among healthcare professionals about the adverse effects of radiation therapy is driving the growth of the Peptide Therapeutics Market. The Metabolic Disorders segment is estimated to be the fastest growing segment with a CAGR of 11.2% over the period 2021-2026. This growth is owing to the factors such as the growing demand for generic peptides for the treatment of metabolic disorders, the rise in the adoption of medical diagnostic devices, and increase in the base of the geriatric population susceptible to metabolic disorders in developed nations.
Peptide Therapeutics Market Segment Analysis-By Geography
North America held the largest share with 31% of the overall market in 2020. The growth in this segment is owing to the factors such as the rise in the adoption of peptides as medical diagnostic devices and the increase in the prescription of peptide therapeutics for the treatment of cancer. The rise in the product launches by key players is driving the growth of the Peptide Therapeutics Market. Asia-Pacific segment is estimated to be the fastest growing segment over the period 2021-2026. The growth in this segment is owing to the factors such as the rise in the adoption of generic peptides for various infectious diseases and growing investment by the key players to develop advanced peptide therapeutics.
Peptide Therapeutics Market Drivers
Increase in the Prevalence of Metabolic Disorders
Owing of their cost-effectiveness, the market for generic peptides has increased as the prevalence of metabolic disorders has increased. The main players are also concentrating on developing advanced peptide therapeutics as a result of the rise in the number of geriatrics in developed countries who are susceptible to metabolic disorders, which is fueling the growth of the Peptide Therapeutics Market.
Rise in the Adoption of Innovative Platforms to Develop Next-Generation Peptide Therapeutics
Biopharmaceutical companies are increasingly focusing on innovative platforms to develop next-generation peptide treatments for immuno-inflammatory diseases. For instance, companies such as Novo Nordisk A/S and Almirall S.A. are investing in PolyXen technology, which is a patent-protected platform technology that develops first-in-class peptide treatments for immuno-inflammatory diseases, which is one of the major factors driving the growth of the Peptide Therapeutics Market.
Download Sample Report @ https://www.industryarc.com/pdfdownload.php?id=17367
Peptide Therapeutics Market Challenges
Stringent Government Regulations
The key players in the market are collaborating with other players to carry out various research and development activities for launching advanced generic peptides for the treatment of various disorders. However, peptide therapeutics require a better regulatory framework, which is one of the major factors that is estimated to reduce the growth of the Peptide Therapeutics Market.
Peptide Therapeutics Market Competitive Landscape:
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Peptide Therapeutics Market. Key companies of this market are Eli Lilly and Company, Pfizer Inc, Bachem Holding AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical, Sanofi, Bristol-Myers Squibb (BMS), GlaxoSmithKline, AstraZeneca PLC, and Novo Nordisk A/S among others.
Acquisitions/Partnerships:
In March 2021, Takeda Pharmaceutical Company Limited has entered into a partnership with Anima Biotech to discover and develop a new class of peptides and protein drugs for genetically-defined neurological diseases.
In December 2020, Eli Lilly has acquired Prevail Therapeutics for an aggregate value of up to $1.04Bn to advance its research and development capabilities on peptide-based therapies with the support of the company portfolio of preclinical neuroscience assets.
Key Takeaways
Geographically, North America Peptide Therapeutics Market accounted for the highest revenue share in 2020 and it is poised to dominate over the period 2021-2026 owing to the rise in the adoption of peptides as medical diagnostic devices.
The cancer category is being driven by an increase in the prescription of peptide therapeutics for cancer care in developing countries. Government regulations, on the other hand, are said to be one of the major factors limiting the growth of the Peptide Therapeutics Market.
Detailed analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Peptide Therapeutics Market report.
Related Reports:
A. Peptide Synthesis Market
https://www.industryarc.com/Research/Peptide-Synthesis-Market-Research-505605
B. Peptide And Anticoagulant Drugs Market
https://www.industryarc.com/Research/Peptide-And-Anticoagulant-Drugs-Market-Research-505689
For more Lifesciences and Healthcare Market reports, please click here
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.
